Neurocrine Biosciences, Inc. (NBIX) Stock Forecast & Price Target
Price as of Nov 18, 2026 close · Analyst estimates retrieved Nov 17, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Neurocrine Biosciences, Inc. (NBIX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Neurocrine Biosciences, Inc., analysts forecast revenue rising from $2.84B in 2025 to $5.52B in 2030; the average estimate for 2030 earnings per share is $13.75; with published estimates ranging from $12.97 to $15.29; 21 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Neurocrine Biosciences, Inc. (NBIX) forecast — frequently asked questions
What is the analyst price target for Neurocrine Biosciences, Inc.?
Analysts covering Neurocrine Biosciences, Inc. (NBIX) have a consensus price target of $203.41, 24.9% above the current price of $162.86. Published targets range from $165.00 to $225.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Neurocrine Biosciences, Inc.'s earnings?
The average analyst estimate for Neurocrine Biosciences, Inc. (NBIX) earnings per share in 2030 is 13.75, with individual estimates between 12.97 and 15.29.
How much revenue is Neurocrine Biosciences, Inc. expected to make?
Analysts forecast Neurocrine Biosciences, Inc. (NBIX) revenue of $5.52B in 2030, based on 14 published estimates.
How many analysts cover NBIX?
21 analysts contribute estimates for Neurocrine Biosciences, Inc. (NBIX). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.